BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Au KP, Chok KSH. Immunotherapy after liver transplantation: Where are we now? World J Gastrointest Surg 2021; 13(10): 1267-1278 [PMID: 34754394 DOI: 10.4240/wjgs.v13.i10.1267]
URL: https://www.wjgnet.com/1948-9366/full/v13/i10/1267.htm
Number Citing Articles
1
Coskun Ozer Demirtas, Feyza Gunduz. Programmed Cell Death 1 and Hepatocellular Carcinoma: An Epochal StoryJournal of Gastrointestinal Cancer 2021; 52(4): 1217 doi: 10.1007/s12029-021-00758-z
2
Karen Abboud, Godsfavour Umoru, Abdullah Esmail, Ala Abudayyeh, Naoka Murakami, Humaid O. Al-Shamsi, Milind Javle, Ashish Saharia, Ashton A. Connor, Sudha Kodali, Rafik M. Ghobrial, Maen Abdelrahim. Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant OncologyCancers 2023; 15(5): 1433 doi: 10.3390/cancers15051433
3
Konstantinos Ouranos, Anthi Chatziioannou, Ioannis Goulis, Emmanouil Sinakos. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantationWorld Journal of Transplantation 2022; 12(11): 331-346 doi: 10.5500/wjt.v12.i11.331
4
Saad Alghamdi, Waleed Al-Hamoudi. Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant OncologyCancers 2023; 15(21): 5115 doi: 10.3390/cancers15215115
5
Charles-Henri Wassmer, Sofia El Hajji, Xenofon Papazarkadas, Philippe Compagnon, Parissa Tabrizian, Stéphanie Lacotte, Christian Toso. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical DataCancers 2023; 15(18): 4574 doi: 10.3390/cancers15184574
6
Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first reportAmerican Journal of Transplantation 2024;  doi: 10.1016/j.ajt.2024.01.007
7
Sai Swarupa R Vulasala, Nirmal K Onteddu, Sindhu P Kumar, Chandana Lall, Priya Bhosale, Mayur K Virarkar. Advances and effectiveness of the immunotherapy after liver transplantationWorld Journal of Gastrointestinal Surgery 2022; 14(6): 629-631 doi: 10.4240/wjgs.v14.i6.629
8
Chia Yuen Chong, Michelle S. Goh, Sandro V. Porceddu, Danny Rischin, Annette M. Lim. The Current Treatment Landscape of Cutaneous Squamous Cell CarcinomaAmerican Journal of Clinical Dermatology 2023; 24(1): 25 doi: 10.1007/s40257-022-00742-8
9
Julian K. Horwitz, Vatche G. Agopian. Indication of Liver Transplant for HCC: Current Status and Future DirectionsCurrent Hepatology Reports 2024; 23(1): 185 doi: 10.1007/s11901-024-00641-y
10
Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Thomas Talbot, Alessandra Gennari, Mark R. Openshaw, Coskun O. Demirtas, Alessio Cortellini, David J. Pinato. New Frontiers in the Medical Therapy of Hepatocellular CarcinomaChemotherapy 2022; 67(3): 164 doi: 10.1159/000521837
11
Nora Alzahrani, Ayman Al Jurdi, Leonardo V. Riella. Immune checkpoint inhibitors in kidney transplantationCurrent Opinion in Organ Transplantation 2023; 28(1): 46 doi: 10.1097/MOT.0000000000001036
12
Landon L. Chan, Stephen L. Chan. The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatmentClinical and Molecular Hepatology 2023; 29(4): 909 doi: 10.3350/cmh.2023.0114
13
Anand V. Kulkarni, Vamsi Krishna, Karan Kumar, Mithun Sharma, Bharat Patodiya, Arif Khan, Sameer Shaik, Ashirwad Pasumarthy, Prateek Chhabra, Pramod Kumar Da, Vivek A. Saraswat, Padaki N. Rao, Duvvur N. Reddy. Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian ExperienceJournal of Clinical and Experimental Hepatology 2023; 13(4): 618 doi: 10.1016/j.jceh.2023.02.003
14
Stefano Kayali, Andrea Pasta, Maria Corina Plaz Torres, Ariel Jaffe, Mario Strazzabosco, Simona Marenco, Edoardo G. Giannini. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysisLiver International 2023; 43(1): 8 doi: 10.1111/liv.15419
15
Kathrine S Rallis, Dimitrios Makrakis, Ioannis A Ziogas, Georgios Tsoulfas. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advancesWorld Journal of Clinical Oncology 2022; 13(6): 448-472 doi: 10.5306/wjco.v13.i6.448
16
Stephanie Ji, Hao Liu, Laura Pachella, Ryan D. Stephenson, Roman Groisberg, Sarah A. Weiss. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignanciesFrontiers in Transplantation 2023; 2 doi: 10.3389/frtra.2023.1284740
17
Anthony C. Bejjani, Richard S. Finn. Hepatocellular Carcinoma: Pick the Winner—Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent–Based CombinationsJournal of Clinical Oncology 2022; 40(24): 2763 doi: 10.1200/JCO.21.02605
18
Zurabi Lominadze, Kareen Hill, Mohammed Rifat Shaik, Justin P. Canakis, Mohammad Bourmaf, Cyrus Adams-Mardi, Ameer Abutaleb, Lopa Mishra, Kirti Shetty. Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A ReviewInternational Journal of Molecular Sciences 2023; 24(3): 2358 doi: 10.3390/ijms24032358